Why Is CLIMB BIO INC (CLYM) Stock Moving Today?

Climb Bio Inc (CLYM) stock rose 6.24% to $15.50 in morning trading on Thursday as multiple analysts raised their price targets following encouraging Phase 1 trial data for its CLYM116 compound. The stock opened at $14.60 and reached a session high of $15.50 at 10:00 AM ET, with volume at 0.3 million shares, or 0.2 times the 3-month average.

What Happened

The stock’s upward move was driven by a series of analyst upgrades. B. Riley raised its price target to $30 from $26, BTIG increased its target to $32 from $20, and Baird raised its target to $25 from $21. Piper Sandler also raised its target to $40 from $23. These actions followed the release of Phase 1 data showing that a single 320 mg dose of CLYM116 suppressed APRIL by more than 90% and IgA by 60-75% for 12 weeks in healthy volunteers. The data has generated optimism about the drug’s potential in treating IgA nephropathy, with Phase 2 data expected in the first half of 2027.

What The Data Shows

The stock has traded between $1.54 and $18.33 over the past 52 weeks. It reached an 8-session high on September 4, printing 11 fresh 52-week highs and one 52-week low. The stock has a market cap of $864.4 million, a beta of 0.08, and an unprofitable earnings profile with a trailing twelve-month EPS of -0.83. Over the last eight sessions, the stock declined 9.3% from $16.40 to $14.87 before today’s rebound.

What To Watch

Investors should monitor the company’s Phase 2 IgA nephropathy data, expected in H1 2027, as well as continued analyst coverage. The stock’s recent volatility and analyst activity suggest ongoing interest in the company’s pipeline.